Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OBT and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia

Published: Thursday, January 02, 2014
Last Updated: Wednesday, January 01, 2014
Bookmark and Share
First clinical development candidate in $1 billion oncology investment alliance.

Oxford BioTherapeutics (OBT) and Berlin-Chemie (Menarini Group) have announced that they have designated a novel enhanced antibody targeting acute myeloid leukemia (AML) as the first clinical development candidate under the companies’ strategic oncology collaboration.

The companies have initiated formal regulatory enabling studies to support an application for a clinical phase I trial in AML patients in H2 2014.

OBT and Menarini established their strategic partnership in October 2012, covering the development and commercialization of five of OBT’s proprietary antibody-based cancer therapies.

Under the collaboration, Menarini contributes manufacturing, regulatory, pre-clinical, clinical and expertise, supported by investment of up to $1.1 billion.

Futhermore Menarini is responsible for the clinical development, first up to the clinical proof of concept study, then to the full development and regulatory approval in its territories: Europe, Asia, and Latin America, while OBT is responsible for full development, approval and commercialization in North America and Japan.

The first of the partnership’s programs to progress into clinical development is an engineered antibody designed to induce antibody-dependent cellular cytotoxicity (ADCC) in AML and related hematological cancers. This first-in-class therapeutic incorporates BioWa ADCC-enhancing technology and has completed the in vitro/ex vivo proof-of-concept, demonstrating efficacy, and exploratory toxicology testing.

The manufacturing process has been transferred and scaled-up at Menarini Biotech. Further regulatory pre-clinical studies and ex vivo experiments on AML blasts are now underway by Menarini.

“We welcome the achievement of this strategic milestone in our partnership with Menarini,” said Dr Christian Rohlff, Oxford BioTherapeutics’ CEO and Founder. “This is an important first step in accelerating the clinical development of our pipeline of novel antibody-based cancer therapeutics. As a leading international pharmaceutical company, Menarini has a growing presence in the cancer research field, and we look forward to progressing additional oncology programs as part of our alliance.”

“The aim of the partnership between the Menarini Group and OBT", declared Andrew Slade, CEO of Menarini Biotech, "is to focus on cancer research where the available treatments are not very effective. The study of antibodies, that is biological drugs, capable of attacking and destroying the blasts, the carcinogenic cells responsible for this type of leukaemia, is one of the areas our research groups are concentrating on. The first result of our researchers has arrived after a year of intense work, in the form of a monoclonal antibody which shows a remarkable ability to identify the target cells and induce their elimination.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim
License for development and commercialization of antibody products to an oncology target.
Thursday, January 15, 2015
Oxford BioTherapeutics Appoints Dr Eugen Leo
Dr. Leo will be responsible for driving the Company’s pipeline of ADCs into clinical development.
Thursday, July 10, 2014
Oxford BioTherapeutics Appoints Dr Keith E Wilson as Chief Scientific Officer
Dr Wilson brings over 20 years’ experience of life sciences research and development to the Company.
Thursday, June 19, 2014
Oxford BioTherapeutics Takes Exclusive Rights to Use Xenomouse® Antibodies and ADC Technology
Company to develop novel antibody-drug conjugate for HER2-negative breast cancer.
Friday, May 16, 2014
Menarini and OBT Sign Major Strategic Collaboration
Strategic alliance for the clinical development and manufacture of a portfolio of novel antibody-based cancer drugs.
Tuesday, October 30, 2012
OBT Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
Dr Begley brings extensive knowledge and expertise to OBT at an exciting phase in the company’s development.
Thursday, January 12, 2012
Scientific News
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!